abstract: Four lines of @entity0 , two lines selected for rapid growth (large body weights) (M16 and H6) and their unselected control lines (ICR and C2, respectively), were examined for traits related to @entity1 . The M16 line is @entity1 while the other three lines are normal in body composition at 10 weeks of age when fed stock diet. In experiment I, @entity0 were fed stock diet and examined at intervals from 4 to 22 weeks of age. @entity0 were fed either a high- @entity6 or high-fat diet in experiment II and examined at 4, 6 and 10 weeks of age. The traits measured were serum @entity2 , serum insulin and in vitro insulin responsiveness of diaphragm muscle. Epididymal adipose cellularity was determined at 10 weeks of age. Insulin responsiveness was determined for the diaphragm muscle by @entity3 uptake. Body weights differed significantly (M16 greater than H6 greater than ICR greater than C2, P less than 0.01). The M16 @entity1 line was @entity4 and mildly @entity5 while the H6 line was hypoglycemic and normoinsulinemic. Basal @entity3 uptakes by diaphragm muscle were similar among lines while the insulin-stimulated uptake by M16 and H6 lines was less (P less than 0.01) than the stimulated uptake by their control lines. Diet did not affect basal uptakes, but high-fat diets reduced (P less than 0.01) the insulin stimulated uptakes when compared to the high- @entity6 diet. Selected lines had more and larger epididymal adipocytes than control lines when fed the stock diet (P less than 0.01). Decreased insulin responsiveness of muscle tissue among the lines occurred concomitantly with an increase in adipocyte size.

title: Insulin responsiveness of diaphragm tissue and adipose cellularity in XXXX selected for rapid growth.

answer: @entity0


abstract: Marine cetaceans (whales and dolphins), pinnipeds (seals and sea lions), reptiles (turtles and crocodyles), fish and shellfish, and fish-eating birds have been found to harbor salmonellae. In some of these animals, clinical @entity2 has been demonstrated, but in many cases, the isolated salmonellae may have been an opportunistic pathogen with the illness or @entity1 of the host due to other causes. On the basis of the few reports in the literature, marine reptiles (turtles and crocodyles), fish, and shellfish appear to be passive carriers of salmonellae and demonstrate no clinical disease. All of these animals constitute a potential source of @entity2 in @entity0 and his domestic animals. The role of wild and domestic terrestrial animals and fresh water aquatic animals in the transmission of @entity2 to @entity0 has been recognized for many years. The situation with regard to the marine (saltwater) animals has never been adequately investigated or reported. In the past, much reliance has been placed on the ability of saline waters to inhibit or destroy @entity0 pathogens, including the salmonellae. Whether this effect is chemical, physical or biological has been studied since the late nineteenth century, and the investigators have found a number of factors affecting both the inhibition and stimulation of growth of salmonellae in saline waters. Salmonellae have been isolated from or found to survive in seawater with salinities as high as 3.5 percent. Marine animals in many parts of the world have been found harboring salmonellae.

title: XXXX in the marine environment. A review and commentary.

answer: @entity2


abstract: Developmental changes of @entity0 ( @entity0 ) neurons and fibers in the spinal cord of the embryo and posthatching @entity1 were studied with immunohistochemical techniques with the aid of an antibody against @entity0 . The first @entity0 -immunoreactive fibers were found in the marginal layer of the cervical and lumbar spinal cord on embryonic days 6 and 8, respectively. There was a time lag of a few days between the first appearance of @entity0 fibers in the marginal layer (embryonic days 6-8) and the time of penetration of @entity0 fibers into the mantle layer (embryonic day 8 or older). The developments of @entity0 innervation in the rostral parts of the spinal cord precedes that of caudal regions. @entity0 fibers penetrating into the mantle layer of the lumbar spinal cord were first found in lamina VII on embryonic day 8, whereas there were no @entity0 -immunoreactive fibers in lamina IX by embryonic day 10. Large differences were found between embryonic day 16 and posthatching day 5 with regard to the density of @entity0 varicosities and fibers in lamina IX, where profiles of soma and large-sized dendrites were heavily covered with varicosities. Laminae I and II first received @entity0 fibers on embryonic day 16 and had a much denser innervation by posthatching day 5. There were no traces of @entity0 fibers in lamina III in the stages examined up to posthatching day 5. @entity0 fibers were located in the lateral and ventral marginal layers in all specimens examined; only a few fibers were found in the dorsal marginal layer. Although few, @entity0 -immunoreactive cell bodies were found in an area around the central canal of all animals from embryonic day 8 to adult. Some of these were located in the ependymal layer and sent processes toward the central canal; there were a small number of cells with long, fine processes. @entity0 -immunoreactive fibers in the spinal cord were not altered in regions rostral to the spinal transection, whereas all the serotoninergic fibers of the supraspinal origin were eliminated in the spinal cord caudal to the gap.

title: Immunohistochemical study on the development of serotoninergic neurons in the XXXX : II. Distribution of cell bodies and fibers in the spinal cord.

answer: @entity1


abstract: A survey was undertaken of the occurrence, serotype, antimicrobial sensitivity and plasmid content of members of the tribe Proteeae in the environment of two @entity1 -rearing units in the county of Avon in South West England. Examples of the following species were found: @entity5 , Prot. vulgaris, Prot. vulgaris Biogroup 2, @entity7 , @entity6 , Prov. alcalifaciens and Prov. rettgeri. A wide range of serotypes was found, many having been previously reported from nosocomial isolates. A total of 15% of isolates carried plasmids; six pairs of isolates were identified which had identical serotypes but different patterns of plasmid carriage. The antimicrobial sensitivity of the isolates was generally similar to isolates of Proteeae from @entity0 . Although no truly @entity3 -resistant isolates were found, some isolates of Prov. stuartii and Prov. rettgeri had MIC's higher than the other isolates to @entity2 and @entity4 , suggesting the presence of low levels of the enzyme AAC 2'. The study demonstrates that there is a considerable diversity of species and types of Proteeae associated with @entity1 and their environment. It seems likely that a potential cause of colonization of the @entity0 gut by Proteeae is the consumption of meat.

title: Speciation, serotyping, antimicrobial sensitivity and plasmid content of Proteeae from the environment of XXXX -rearing units in South West England.

answer: @entity1


abstract: In several diseases, such as disseminated @entity5 , fibrin- @entity3 degradation products ( @entity4 ) can be detected when serum is used. To avoid the use of serum with the risk of falsely positive and negative results, and to quantitatively measure routinely low levels of @entity4 in plasma, we developed a solid-phase enzyme immunoassay (EIA), using a monoclonal antibody (No. @entity4 -14). It reacts specifically with @entity4 , but not with the parent @entity3 -fibrin molecule. To raise the monoclonal antibodies we injected into @entity1 a whole mixture of fibrin degradation products isolated after complete lysis of a @entity0 blood clot by tissue-type plasminogen activator, because there is a chance that such products resemble @entity4 in @entity0 ' blood more closely than antigens derived from purified @entity3 . The EIA developed is a two-step assay ("cap-tag procedure"), in which the monoclonal antibody is attached to the wells of microtiter plates. The monoclonal antibody is specific for a neoantigenic determinant in the fragment E moiety, exposed after degradation of @entity3 -fibrin by plasmin. The assay discriminates neither between degradation products of @entity3 and fibrin nor between fibrin degradation products that are or are not cross-linked. It is not disturbed by the presence of @entity3 or fibrin monomer in plasma. The assay is accurate above 60 ng @entity4 per milliliter and has a detection limit down to approximately 10 ng @entity4 per milliliter when the supernatant of a lysed blood clot is used as calibration material. In frozen, then thawed plasma specimens from normal individuals, @entity4 values varied between 30 and 110 ng/ml. Plasma of @entity0 with disseminated @entity5 and of @entity0 receiving thrombolytic therapy had increased @entity4 values. In @entity0 with @entity2 , @entity4 concentrations in plasma varied with the clinical course of the disease. Results indicate that the EIA for @entity4 in plasma is promising as a diagnostic tool in different clinical situations.

title: New enzyme immunoassay of fibrin- XXXX degradation products in plasma using a monoclonal antibody.

answer: @entity3


abstract: The tRNA-like structure of @entity9 is known to be efficiently recognized and aminoacylated by valyl-tRNA synthetase. The present work reports domains in the isolated tRNA-like fragment (159 terminal @entity4 at the 3'-end of the two viral RNAs) in contact with purified @entity1 valyl-tRNA synthetase. These domains were determined in protection experiments using chemical and enzymatic structural probes. In addition, new data, re-enforcing the validity of the tertiary folding model for the native RNA, are given. In particular, at the level of the @entity2 accepting arm it was found that the two @entity3 groups flanking the three @entity5 residues of loop I are inaccessible to @entity0 . This is in agreement with a higher-order structure of this loop involving "pseudo knotting", as proposed by Rietveld et al. (1982). @entity8 -tRNA synthetase efficiently protects the viral RNA against digestion by single-strand-specific S1 nuclease at the level of the anticodon loop. With cobra venom ribonuclease, specific for double-stranded regions of RNA, protection was detected on both sides of the anticodon arm and at the 5'-ends of loop I, a region that is involved in the building up of the acceptor arm. Loop II, which is topologically homologous to the T-loop of canonical tRNA was likewise protected. Weak protection was observed between arms I and II, and at the 3'-side of arm V. This arm, located at the 5'-side of arm IV (homologous to the D-arm of tRNA), does not participate in the pseudo-knotted model of the @entity6 acceptor arm. Ethylnitrosourea was used to determine the @entity7 of the tRNA-like structure in close contact with the synthetase. These are grouped in several stretches scattered over the RNA molecule. In agreement with the nuclease digestion results, protected @entity7 are located in arms I, II, and III. Additionally, this chemical probe permits detection of other protected @entity7 on the 3'-side of arm IV and on both sides of arm V. When displayed in the three-dimensional model of the tRNA-like structure, protected areas are localized on both limbs of the L-shaped RNA. It appears that valyl-tRNA synthetase embraces the entire tRNA-like structure. This is reminiscent of the interaction model of canonical @entity1 tRNAVal with its cognate synthetase.

title: Contact areas of the XXXX tRNA-like structure interacting with @entity1 valyl-tRNA synthetase.

answer: @entity9


abstract: The tRNA-like structure of @entity9 is known to be efficiently recognized and aminoacylated by valyl-tRNA synthetase. The present work reports domains in the isolated tRNA-like fragment (159 terminal @entity4 at the 3'-end of the two viral RNAs) in contact with purified @entity1 valyl-tRNA synthetase. These domains were determined in protection experiments using chemical and enzymatic structural probes. In addition, new data, re-enforcing the validity of the tertiary folding model for the native RNA, are given. In particular, at the level of the @entity2 accepting arm it was found that the two @entity3 groups flanking the three @entity5 residues of loop I are inaccessible to @entity0 . This is in agreement with a higher-order structure of this loop involving "pseudo knotting", as proposed by Rietveld et al. (1982). @entity8 -tRNA synthetase efficiently protects the viral RNA against digestion by single-strand-specific S1 nuclease at the level of the anticodon loop. With cobra venom ribonuclease, specific for double-stranded regions of RNA, protection was detected on both sides of the anticodon arm and at the 5'-ends of loop I, a region that is involved in the building up of the acceptor arm. Loop II, which is topologically homologous to the T-loop of canonical tRNA was likewise protected. Weak protection was observed between arms I and II, and at the 3'-side of arm V. This arm, located at the 5'-side of arm IV (homologous to the D-arm of tRNA), does not participate in the pseudo-knotted model of the @entity6 acceptor arm. Ethylnitrosourea was used to determine the @entity7 of the tRNA-like structure in close contact with the synthetase. These are grouped in several stretches scattered over the RNA molecule. In agreement with the nuclease digestion results, protected @entity7 are located in arms I, II, and III. Additionally, this chemical probe permits detection of other protected @entity7 on the 3'-side of arm IV and on both sides of arm V. When displayed in the three-dimensional model of the tRNA-like structure, protected areas are localized on both limbs of the L-shaped RNA. It appears that valyl-tRNA synthetase embraces the entire tRNA-like structure. This is reminiscent of the interaction model of canonical @entity1 tRNAVal with its cognate synthetase.

title: Contact areas of the @entity9 tRNA-like structure interacting with XXXX valyl-tRNA synthetase.

answer: @entity1


abstract: Finely divided, insoluble inulin (gamma polymorph), given intraperitoneally (i.p.) to C57BL @entity0 1-3 days after i.p. B16 @entity1 cells, very significantly increased their @entity3 ( @entity3 ) in low doses (less than or equal to 40 and less than or equal to 100 micrograms/ @entity0 in 50 and 80% of tests, respectively). The gamma inulin was pure and free of endotoxin and soluble inulin, and was developed as a potent reagent specific for activating the @entity2 ( @entity2 ). Its antitumour action paralleled its in vitro @entity2 activation, namely, both activities were sharply dose-dependent up to a threshold dose above which they were dose-independent; dissolved inulin was inactive in vitro and in vivo, decreased the @entity3 of the @entity0 and in a mixture antagonized the in vitro and in vivo activities of gamma inulin; the more soluble (alpha) polymorphs were active in proportion to their gamma content but the effects were blocked at higher doses presumably by dissolved inulin. In addition, depletion of host @entity2 with cobra venom factor or inulin before giving B16 cells increased their malignancy and abrogated the subsequent antitumour action of gamma inulin. The minimum i.p. dose of gamma inulin found to activate serum @entity2 in vivo was 50 micrograms (2.5 mg/kg), i.e. close to the minimum antitumour dose. These close correlations and the specificity of the reagent indicate that activation in vivo of the @entity2 (cellular or humoral) is an important first contact in stimulating host antitumour defences in this @entity0 model.

title: The anti- XXXX activity of inulin in @entity0 .

answer: @entity1


abstract: Finely divided, insoluble inulin (gamma polymorph), given intraperitoneally (i.p.) to C57BL @entity0 1-3 days after i.p. B16 @entity1 cells, very significantly increased their @entity3 ( @entity3 ) in low doses (less than or equal to 40 and less than or equal to 100 micrograms/ @entity0 in 50 and 80% of tests, respectively). The gamma inulin was pure and free of endotoxin and soluble inulin, and was developed as a potent reagent specific for activating the @entity2 ( @entity2 ). Its antitumour action paralleled its in vitro @entity2 activation, namely, both activities were sharply dose-dependent up to a threshold dose above which they were dose-independent; dissolved inulin was inactive in vitro and in vivo, decreased the @entity3 of the @entity0 and in a mixture antagonized the in vitro and in vivo activities of gamma inulin; the more soluble (alpha) polymorphs were active in proportion to their gamma content but the effects were blocked at higher doses presumably by dissolved inulin. In addition, depletion of host @entity2 with cobra venom factor or inulin before giving B16 cells increased their malignancy and abrogated the subsequent antitumour action of gamma inulin. The minimum i.p. dose of gamma inulin found to activate serum @entity2 in vivo was 50 micrograms (2.5 mg/kg), i.e. close to the minimum antitumour dose. These close correlations and the specificity of the reagent indicate that activation in vivo of the @entity2 (cellular or humoral) is an important first contact in stimulating host antitumour defences in this @entity0 model.

title: The anti- @entity1 activity of inulin in XXXX .

answer: @entity0


abstract: @entity0 with @entity7 initially respond to a number of therapies but relapse is common and inexorable with time, and despite further therapy, most @entity0 will ultimately die of their @entity4 . The recent demonstration of their sensitivity to alpha-interferon is promising. The importance of this human antitumor effect is that it is presumably based on mechanisms different from conventional agents. Phase I trials of various doses and schedules of recombinant alpha-interferon have shown that effective serum levels can be obtained by intramuscular (IM), intravenous (IV), or subcutaneous (SC) routes. Virtually all @entity0 experienced some degree of acute @entity2 manifested by fever, chills, @entity5 , and @entity1 . Tolerance usually developed to acute adverse effects within the first few weeks of therapy, regardless of dose or schedule. Fatigue and @entity3 were the most important adverse reactions, occurring during the first two weeks of treatment and generally persisting for the duration of therapy. Occasional adverse effects relating to the central nervous and cardiovascular systems have been reported. Primary laboratory abnormalities observed during treatment include @entity6 and elevations of liver function tests. The clinical efficacy of alpha-interferon, both natural and recombinant, has been demonstrated in both untreated and heavily pretreated @entity0 with @entity7 . The response rate has approached 50% in recent studies; however, less than half were complete responders. Future directions include combination of interferon with cytotoxic agents or other biological response modifiers and use as adjuvant therapy.

title: Alpha-interferon in the treatment of XXXX .

answer: @entity7


abstract: @entity5 is a curable disease that has recently been recognized with increasing frequency. A renal scan in a 1-month-old @entity1 white male showed diminished function of the right kidney, and his peripheral vein @entity4 was elevated. Multiple antihypertensive medications failed to control his @entity1 , and right kidney function deteriorated. An arteriogram showed two stenotic renal arteries supplying the right kidney. The smaller inferior artery supplied 35% of the kidney. Selective vein @entity4 levels were greater than 15,000 ng/dL on the right side. Technical considerations in the repair of this lesion included midline transabdominal incision to expose the abdominal aorta and the inferior vena cava; dissection of inferior vena cava (IVC) with division of selected lumbar veins; full mobilization of right kidney and transsection of both @entity0 with cold Sach's solution after resection of arterial stenoses; end-to-side microvascular @entity2 of the smaller (2 mm) renal artery to the main renal artery at the hilum with 10-0 nylon over in situ perfusion cannula; renal artery passed under the IVC to the aorta; and right kidney autotransplanted to a new site on the abdominal aorta with an end-to-side (5.0 mm) renal artery to the aorta and an end-to-side renal vein to IVC @entity2 . Following revascularization, perfusion was excellent and the blood pressure returned to normal. At 6 months follow-up, selective renal vein renins were normal and an arteriogram showed no @entity3 . Meticulous dissection, cold perfusion, microvascular @entity2 , and autotransplantation salvaged this kidney and resolved the @entity1 .

title: Technical consideration in management of XXXX in an infant with double renal arteries.

answer: @entity5


abstract: BACKGROUND: Healthcare-associated @entity2 (HCAIs) endanger safety by increasing morbidity, mortality, and hospital stay. Studies identifying risk factors for @entity4 rarely address the wider determinants of health. However, a well-characterized association exists between increasing social deprivation and poor health outcomes. Therefore it is important to determine whether HCAIs are associated with social deprivation. AIM: To determine the association between social deprivation and the prevalence of @entity4 , in all inpatients in an acute hospital in Scotland on a single day across September and October 2011. METHODS: This study linked Scottish data from the 2011 European Point Prevalence Survey of @entity4 and Antimicrobial Prescribing to the Scottish Morbidity Record 01, a national dataset with @entity3 ( @entity3 ) included. Multivariate logistic regression was used to model @entity4 prevalence against @entity3 quintile. FINDINGS: No overall association was found between @entity3 quintile and prevalence of @entity4 in all inpatients. A significant difference was found between @entity4 prevalence across @entity3 quintile in @entity0 undergoing surgical procedures, with higher prevalence observed with increasing deprivation (P  =  0.0071). Variables associated with @entity4 prevalence were: intensive care specialty, @entity1 and medical specialties, minimum invasive surgery, and all categories of length of stay. CONCLUSION: This study found a significant difference in @entity4 prevalence across @entity3 quintile in @entity0 undergoing surgery. To our knowledge this was the first study to examine the overall association between @entity4 and @entity3 . The findings highlight the broad and comprehensive nature of social deprivation in determining health outcomes.

title: Determining the effect of social deprivation on the prevalence of healthcare-associated XXXX in acute hospitals: a multivariate analysis of a linked data set.

answer: @entity2


abstract: Pharmacokinetic studies and clinical evaluations of @entity2 ( @entity3 ) were carried out in perinatal mothers and @entity0 , and following results were obtained. The @entity3 was promptly absorbed after intravenous injection or intravenous drip infusion in pregnant @entity0 , producing dose-related peak serum levels. Placental transference to the fetus was good. After intravenous injection or intravenous drip infusion of 1.0-2.0 g of @entity3 , drug concentration in umbilical serum and amniotic fluid exceeded MICs of @entity3 against main pathogenic organisms. Levels of @entity3 in umbilical serum ranged 0.2-15.6 micrograms/ml after 1.0 g intravenous injection or intravenous drip infusion, and 0.7-27.2 micrograms/ml after 2.0 g intravenous injection, and those in amniotic fluid were 1.4-21.3 micrograms/ml after 1.0 g administration and 2.0-27.0 micrograms/ml after 2.0 g administration. According to the above results, it is possible to successfully prevent or treat @entity1 by twice a day administration of @entity3 at 1.0-2.0 g/dose. Clinically, @entity3 was effective in the treatment of @entity1 and the prophylaxis of intrauterine @entity1 without any side effect. Moreover, newborn @entity0 delivered from mothers receiving @entity3 treatment did not have any abnormalities in laboratory test. The penetration of @entity3 into mother's milk was low, thus the transfer of @entity3 from milk to newborn @entity0 should be low. The above results demonstrated that @entity3 is a clinically useful antibiotic for the prophylaxis and the treatment of @entity1 .

title: [Pharmacokinetic and clinical studies of XXXX in perinatal period].

answer: @entity2


abstract: Fundamental and clinical studies were carried out on @entity1 ( @entity2 ) in the perinatal period, and the results obtained were summarized below. Following bolus intravenous injection of @entity2 2 g, maternal serum concentrations of @entity2 were as high as 145.3 +/- 17.2 micrograms/ml (mean +/- S.D.) at about 10 minutes, and then gradually decreased to 46.7 micrograms/ml at 2 hours, 5.31 micrograms/ml at 5 hours and 4 minutes, and 1.54 micrograms/ml at 11 hours and 10 minutes. The @entity2 was detected in umbilical cord serum immediately after the administration, and concentrations were 31.0 +/- 1.54 micrograms/ml at about 10 minutes. Although the concentrations gradually decreased thereafter, they were higher than those in maternal serum at 3 hours and later and was 3.00 micrograms/ml at 11 hours and 10 minutes. The @entity2 was detected in amniotic fluid a little later than in umbilical cord serum, and concentrations of @entity2 in amniotic fluid were as low as 1.50 +/- 0.67 micrograms/ml at about 10 minutes after the administration. Concentrations then gradually increased to 12.8 micrograms/ml at 2 hours and 26.5 micrograms/ml at 5 hours and 4 minutes, and even at 11 hours and 10 minutes, they were as high as 14.2 micrograms/ml. The above results demonstrated that the transfer of @entity2 through placental barrier was very rapid and satisfactory. Also, @entity2 showed good transfer into amniotic fluid, as well as sufficient retention, and was considered to be an effective antibiotic for prophylaxis of both fetal @entity0 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Fundamental and clinical studies on XXXX in the perinatal period].

answer: @entity1


abstract: BACKGROUND: @entity2 symptom severity and @entity3 ( @entity3 ) are significant predictors of mortality and disability. However, the relationship between the two is unclear. OBJECTIVE: This meta-analysis assessed the relationship between @entity2 symptom severity and @entity3 in healthy and depressed adults (aged 18  years and over). SEARCH METHODS: The PubMed, Cochrane Library, Google Scholar and ProQuest databases were browsed for relevant English-language studies published from January 2000 to August 2014. SELECTION CRITERIA: Studies reporting a correlation between a @entity2 scale and maximum @entity1 consumption (VO2peak), as well as studies from the data of which such a correlation could be calculated, were included in this analysis. DATA ANALYSIS: Correlation coefficients (CCs) were converted to Fisher's z  values, and the analysis was performed using a random-effects model. Then, summary effects and 95  % confidence intervals (CIs) were converted back to CCs. RESULTS: Sixteen studies (totalling 4039 @entity0 ) were included in this analysis. A modest correlation between @entity2 symptom severity and @entity3 was found (CC -0.16, 95  %  CI -0.21 to -0.10), appearing stronger in male @entity0 (CC  -  0.22, 95  %  CI -0.26 to -0.18) than in female @entity0 (CC -0.12, 95  %  CI -0.19 to -0.05; p  =  0.01). There was no difference in the summary effect between healthy and depressed adults (p  =  0.43). Heterogeneity was moderate (I (2)  =  33  %; p  =  0.09). CONCLUSIONS: @entity2 symptom severity is inversely correlated with @entity3 , and this correlation is stronger in @entity0 than in @entity0 . Clinical and prognostic implications of the correlation are discussed. These findings should stimulate further research on the effects of treating one variable on the other.

title: @entity2 Symptom Severity and XXXX in Healthy and Depressed Adults: A Systematic Review and Meta-Analysis.

answer: @entity3


abstract: BACKGROUND: @entity2 symptom severity and @entity3 ( @entity3 ) are significant predictors of mortality and disability. However, the relationship between the two is unclear. OBJECTIVE: This meta-analysis assessed the relationship between @entity2 symptom severity and @entity3 in healthy and depressed adults (aged 18  years and over). SEARCH METHODS: The PubMed, Cochrane Library, Google Scholar and ProQuest databases were browsed for relevant English-language studies published from January 2000 to August 2014. SELECTION CRITERIA: Studies reporting a correlation between a @entity2 scale and maximum @entity1 consumption (VO2peak), as well as studies from the data of which such a correlation could be calculated, were included in this analysis. DATA ANALYSIS: Correlation coefficients (CCs) were converted to Fisher's z  values, and the analysis was performed using a random-effects model. Then, summary effects and 95  % confidence intervals (CIs) were converted back to CCs. RESULTS: Sixteen studies (totalling 4039 @entity0 ) were included in this analysis. A modest correlation between @entity2 symptom severity and @entity3 was found (CC -0.16, 95  %  CI -0.21 to -0.10), appearing stronger in male @entity0 (CC  -  0.22, 95  %  CI -0.26 to -0.18) than in female @entity0 (CC -0.12, 95  %  CI -0.19 to -0.05; p  =  0.01). There was no difference in the summary effect between healthy and depressed adults (p  =  0.43). Heterogeneity was moderate (I (2)  =  33  %; p  =  0.09). CONCLUSIONS: @entity2 symptom severity is inversely correlated with @entity3 , and this correlation is stronger in @entity0 than in @entity0 . Clinical and prognostic implications of the correlation are discussed. These findings should stimulate further research on the effects of treating one variable on the other.

title: XXXX Symptom Severity and @entity3 in Healthy and Depressed Adults: A Systematic Review and Meta-Analysis.

answer: @entity2


abstract: AIMS: To examine the bi-directional relationship, whereby hypoglycaemia is a risk factor for @entity3 , and where @entity3 increases risk of hypoglycaemia in older @entity0 with @entity1 treated with @entity4 -lowering agents. METHODS: We searched MEDLINE and EMBASE over a 10-year span from 2005 to 2015 (with automated PubMed updates to August 2015) for observational studies of the association between hypoglycaemia and @entity2 or @entity3 in @entity0 aged >55   years. Assessment of study validity was based on ascertainment of hypoglycaemia, @entity3 and risk of confounding. We conducted random effects inverse variance meta-analyses, and assessed heterogeneity using the I(2) statistic. RESULTS: We screened 1177 citations, and selected 12 studies, of which nine were suitable for meta-analysis. There were a total of 1   439   818 @entity0 , with a mean age of 75   years. Meta-analysis of five studies showed a significantly increased risk of @entity3 in @entity0 who had hypoglycaemic episodes: pooled odds ratio 1.68 [95% confidence interval (CI) 1.45, 1.95]. We also found a significantly increased risk of hypoglycaemia in @entity0 with @entity3 : pooled odds ratio from five studies 1.61 (95% CI 1.25, 2.06). Limitations of the study were heterogeneity in the meta-analysis, and uncertain ascertainment of @entity3 and hypoglycaemic outcomes and temporal relationships. Publication bias may have favoured the reporting of more significant findings. CONCLUSIONS: Our meta-analysis shows a bi-directional relationship between @entity2 and hypoglycaemia in older @entity0 . @entity4 -lowering therapy should be carefully tailored and monitored in older @entity0 who are susceptible to @entity2 .

title: Bi-directional interaction between hypoglycaemia and XXXX in elderly @entity0 treated with @entity4 -lowering agents: a systematic review and meta-analysis.

answer: @entity2


abstract: AIMS: To examine the bi-directional relationship, whereby hypoglycaemia is a risk factor for @entity3 , and where @entity3 increases risk of hypoglycaemia in older @entity0 with @entity1 treated with @entity4 -lowering agents. METHODS: We searched MEDLINE and EMBASE over a 10-year span from 2005 to 2015 (with automated PubMed updates to August 2015) for observational studies of the association between hypoglycaemia and @entity2 or @entity3 in @entity0 aged >55   years. Assessment of study validity was based on ascertainment of hypoglycaemia, @entity3 and risk of confounding. We conducted random effects inverse variance meta-analyses, and assessed heterogeneity using the I(2) statistic. RESULTS: We screened 1177 citations, and selected 12 studies, of which nine were suitable for meta-analysis. There were a total of 1   439   818 @entity0 , with a mean age of 75   years. Meta-analysis of five studies showed a significantly increased risk of @entity3 in @entity0 who had hypoglycaemic episodes: pooled odds ratio 1.68 [95% confidence interval (CI) 1.45, 1.95]. We also found a significantly increased risk of hypoglycaemia in @entity0 with @entity3 : pooled odds ratio from five studies 1.61 (95% CI 1.25, 2.06). Limitations of the study were heterogeneity in the meta-analysis, and uncertain ascertainment of @entity3 and hypoglycaemic outcomes and temporal relationships. Publication bias may have favoured the reporting of more significant findings. CONCLUSIONS: Our meta-analysis shows a bi-directional relationship between @entity2 and hypoglycaemia in older @entity0 . @entity4 -lowering therapy should be carefully tailored and monitored in older @entity0 who are susceptible to @entity2 .

title: Bi-directional interaction between hypoglycaemia and @entity2 in elderly @entity0 treated with XXXX -lowering agents: a systematic review and meta-analysis.

answer: @entity4


abstract: AIMS: To examine the bi-directional relationship, whereby hypoglycaemia is a risk factor for @entity3 , and where @entity3 increases risk of hypoglycaemia in older @entity0 with @entity1 treated with @entity4 -lowering agents. METHODS: We searched MEDLINE and EMBASE over a 10-year span from 2005 to 2015 (with automated PubMed updates to August 2015) for observational studies of the association between hypoglycaemia and @entity2 or @entity3 in @entity0 aged >55   years. Assessment of study validity was based on ascertainment of hypoglycaemia, @entity3 and risk of confounding. We conducted random effects inverse variance meta-analyses, and assessed heterogeneity using the I(2) statistic. RESULTS: We screened 1177 citations, and selected 12 studies, of which nine were suitable for meta-analysis. There were a total of 1   439   818 @entity0 , with a mean age of 75   years. Meta-analysis of five studies showed a significantly increased risk of @entity3 in @entity0 who had hypoglycaemic episodes: pooled odds ratio 1.68 [95% confidence interval (CI) 1.45, 1.95]. We also found a significantly increased risk of hypoglycaemia in @entity0 with @entity3 : pooled odds ratio from five studies 1.61 (95% CI 1.25, 2.06). Limitations of the study were heterogeneity in the meta-analysis, and uncertain ascertainment of @entity3 and hypoglycaemic outcomes and temporal relationships. Publication bias may have favoured the reporting of more significant findings. CONCLUSIONS: Our meta-analysis shows a bi-directional relationship between @entity2 and hypoglycaemia in older @entity0 . @entity4 -lowering therapy should be carefully tailored and monitored in older @entity0 who are susceptible to @entity2 .

title: Bi-directional interaction between hypoglycaemia and @entity2 in elderly XXXX treated with @entity4 -lowering agents: a systematic review and meta-analysis.

answer: @entity0


abstract: PURPOSE: Retrospective analysis of irAEs in @entity3 @entity0 treated with nivolumab. EXPERIMENTAL DESIGN: Data were pooled from 148 @entity0 (33 resected, 115 unresectable) treated with nivolumab plus peptide vaccine or nivolumab alone every 2 weeks for 12 weeks. @entity0 with stable disease or regression received an additional 12-week cycle, then nivolumab alone every 12 weeks for up to 2 additional years. Frequency, grade, and characteristics of immune-related adverse events (irAE) were analyzed. A 12-week landmark survival analysis using a multivariate time-dependent Cox proportional hazard model assessed difference in @entity4 ( @entity4 ) in the presence or absence of irAEs. RESULTS: IrAEs of any grade were observed in 68.2% of @entity0 (101 of 148). Grade III/IV irAEs were infrequent: 3 (2%) had @entity6 , 2 (1.35%) had asymptomatic grade III elevation in amylase/lipase, and 2 (1.35%) had @entity7 . A statistically significant @entity4 difference was noted among @entity0 with any grade of irAE versus those without (P  <= 0.001), and @entity4 benefit was noted in @entity0 who reported three or more irAE events (P  <= 0.001). Subset analyses showed statistically significant @entity4 differences with rash [P = 0.001; HR, 0.423; 95% confidence interval (CI), 0.243-0.735] and @entity5 (P = 0.012; HR, 0.184; 95% CI, 0.036-0.94). @entity6 and @entity5 also correlated with statistically significant @entity4 differences in @entity0 with @entity1 (P = 0.004 and P = 0.028, respectively). No significant survival differences were seen with other irAEs ( @entity8 , @entity7 , or @entity2 ). CONCLUSIONS: Cutaneous irAEs are associated with improved survival in @entity3 @entity0 treated with nivolumab, and clinical benefit should be validated in larger prospective analyses. Clin Cancer Res; 1-9.   2015 AACR.

title: Nivolumab in Resected and Unresectable XXXX : Characteristics of Immune-Related Adverse Events and Association with Outcomes.

answer: @entity3


abstract: UNASSIGNED: Background and purpose - During the last decade, many hospitals have implemented fast-track protocols for @entity2 ( @entity2 ). These protocols reduce the length of hospital stay, but there is no literature on the first period after hospital discharge. We determined how @entity0 experienced the first 6 weeks after hospital discharge after fast-track @entity2 surgery. @entity0 and methods - 34 consecutive @entity0 who had @entity2 surgery with fast track received a diary for 6 weeks, which contained various international validated questionnaires. In addition, general questions regarding @entity1 , the wound, physiotherapy, and @entity3 prophylaxis injections were posed. Results - 4 of the 34 @entity0 were excluded during the study. Of the remaining 30 @entity0 , 28 were positive regarding the short length of hospital stay. @entity1 gradually decreased and quality of life and function gradually improved during the 6 weeks. Mean hours of weekly physiotherapy were 0.6 for the first week and 0.9 during the sixth week, with high variance of treatment modalities due to the lack of standardized treatment protocols. Additional clinical consultations were needed in 9 @entity0 during the 6-week period. Interpretation - 28 of 30 @entity0 were satisfied with the short length of hospital stay. The intensity of physiotherapy was surprisingly low. The quality of life 6 weeks after discharge was similar to that before the surgery.

title: The first 6 weeks of recovery after XXXX with fast track.

answer: @entity2


abstract: BACKGROUND: The association between birth position and obstetric @entity1 ( @entity4 ) in spontaneous vaginal deliveries is unclear. METHODS: The study was based on the Stockholm-Gotland Obstetric Database (Sweden) from Jan 1(st) 2008 to Oct 22(nd) 2014 and included 113 279 singleton spontaneous vaginal births with no episiotomy. We studied risk of @entity4 with respect to the following birth positions: a) sitting, b) lithotomy, c) lateral, d) standing on knees, e) birth seat, f) supine, g) squatting, h) standing and i) all fours. All analyses were stratified for parity. General linear models were used to calculate risk ratios (RR) adjusted for maternal, pregnancy and fetal characteristics. RESULTS: The rates of @entity4 among nulliparous @entity0 , parous @entity0 and @entity0 undergoing vaginal birth after a caesarean (VBAC) were 5.7  %, 1.3  % and 10.6  %, respectively. The rates varied by birth position: from 3.7 to 7.1  % in nulliparous @entity0 , 0.6  % to 2.6  % in parous @entity0 and 5.6  % to 18.2  % in @entity0 undergoing VBAC. Regardless of parity, the lowest rates were found among @entity0 giving birth in standing position and the highest rates among @entity0 birthing in the lithotomy position. Compared with sitting position, the lithotomy position involved an increased risk of @entity4 among nulliparous (adjusted RR 1.17, 95  % CI 1.06-1.29) and parous @entity0 (adjusted RR 1.66, 95  % CI 1.35-2.05). Birth seat and squatting position involved an increased risk of @entity4 among parous @entity0 (adjusted RR [95  % CI] 1.36 [1.03-1.80] and 2.16 [1.15-4.07], respectively). Independent risk factors for @entity4 were maternal age, head circumference >= 35  cm, birth weight >= 4000  g, length of gestation   >=    40  weeks, @entity3 , non-occiput anterior presentation and @entity2 augmentation. CONCLUSIONS: Compared with sitting position, lateral position has a slightly protective effect in nulliparous @entity0 whilst an increased risk is noted among @entity0 in the lithotomy position, irrespective of parity. Squatting and birth seat position involve an increase in risk among parous @entity0 .

title: Birth position and obstetric XXXX : a population-based study of 113 000 spontaneous births.

answer: @entity1


abstract: BACKGROUND: The mechanisms by which painful @entity1 are linked to the multitude of @entity2 and neuroplastic changes in the brain remain poorly understood. Here we propose a model that relies on epi-neuronal communication through the vascular system to effect various brain structures. Specifically, we hypothesize that the differential vulnerability of the blood-brain barrier (BBB) in different brain regions is associated with region-specific neuroplastic and neurovascular changes that are in turn associated with particular @entity2 . PRESENTATION OF THE HYPOTHESIS: We will present our hypothesis by focusing on two main points: (A) @entity3 ( @entity3 ) is associated with differential BBB compromise. (B) Circulating mediators leaking through the BBB create cytogenic and neovascular niches associated with @entity2 -related co-morbidities. TESTING THE HYPOTHESIS: Pre-clinically, our hypothesis can be tested by observing, in parallel, BBB compromise, (neo)vascularization, neurogenesis, and their co-localization in @entity2 models using imaging, microscopy, biochemical and other tools. Furthermore, the BBB can be experimentally damaged in specific brain regions, and the consequences of those lesions studied on nociception and associated comorbidities. Recently developed imaging techniques allow the analysis of blood brain barrier integrity in @entity0 providing a route for translation of the laboratory findings. Though perhaps more limited, post-mortem examination of brains with available @entity2 histories constitutes a second approach to addressing this hypothesis. IMPLICATIONS OF THE HYPOTHESIS: Understanding changes in BBB permeability in @entity3 conditions has clear implications both for understanding the pathogenesis of @entity3 and for the design of novel treatments to prevent @entity3 and its consequences. More broadly, this hypothesis may help us to understand how peripheral @entity1 impact the brain via mechanisms other than commonly studied efferent sensory pathways.

title: Novel cytogenic and neurovascular niches due to blood-brain barrier compromise in the XXXX brain.

answer: @entity3


abstract: BACKGROUND: Obesity in the hemodialysis population is roughly twice that of the general population. An @entity3 ( @entity3 ) remains the recommended vascular access; however, @entity2 results in fewer autogenous accesses, more complexity, and higher @entity3 failure rates. We reviewed our vascular access experience in @entity2 individuals in whom the depth of an @entity3 prevented reliable cannulation. STUDY DESIGN: We reviewed our database of consecutive vascular access @entity0 , identifying individuals in whom the planned venous outflow cannulation segments were too deep and required additional surgical procedures to establish a functional hemodialysis access. These additional procedures included lipectomy, outflow elevation, cephalic transposition, liposuction, or an implantable cannulation guide. RESULTS: During the study period, 1,874 consecutive new @entity0 had an autogenous vascular access constructed. We identified 120 @entity0 in whom an additional procedure was required due to the depth of the cannulation sites; these comprised this study group. Ninety-nine (83%) were female, 85 (71%) were @entity1 , and 53 (45%) had previous access operations. Body mass index was 25.4 to 62.8 kg/m(2) (mean 40.8 kg/m(2)), age range was 27 to 81 years (mean 54 years), and follow-up was 1 to 101 months (mean 25 months). Primary and cumulative patency rates for all @entity0 were 63% and 93% at 1 year and 46% and 91% after 2 years, respectively. The most common additional procedure performed was a lipectomy (n  = 78), with 1-year primary and cumulative patency rates of 78% and 97% and 2-year rates of 69% and 91%, respectively. CONCLUSIONS: A variety of surgical options were found to be successful in establishing a functional autogenous vascular access for individuals in whom cannulation sites were simply too deep. Cumulative patency rates for all @entity0 were 93% at 1 year and 91% after 2 years.

title: When XXXX Are Too Deep: Options in Obese Individuals.

answer: @entity3


abstract: BACKGROUND: Adequate lymph node evaluation (LNE) is recommended for surgically treated @entity2 because studies have shown an association between improved survival and adequate LNE. This study aimed to understand the mechanism of this association and determine whether LNE is a valuable quality metric. METHODS: Using the linked Surveillance Epidemiology End Results Medicare database, we identified @entity0 with surgically treated @entity2 from 2000 to 2010. Adequate LNE was defined as evaluation of >= 15 nodes. Survival was determined using Kaplan-Meier and Cox proportional hazards. RESULTS: We identified 2629 @entity0 who underwent resection for @entity2 . Overall, 33  % had adequate LNE. Adequate LNE was significantly associated with receipt of postoperative chemotherapy. A significant decrease in hazard of @entity1 was associated with adequate LNE (HR 0.86, p   <   0.05). Receipt of postoperative chemotherapy was also significantly associated with @entity1 (HR 0.77, p   <   0.05). On unadjusted analysis, the survival benefit associated with adequate LNE was lost when stratified by receipt of postoperative chemotherapy. CONCLUSION: The survival benefit associated with LNE is in part derived from the fact that @entity0 who receive adequate LNE are also more likely to receive chemotherapy. Thus, the use of lymph node counts has limitations as a quality metric.

title: Lymph Node Evaluation for XXXX and Its Value as a Quality Metric.

answer: @entity2


abstract: UNASSIGNED: The H1 haplotype of the 17q21.31 inversion polymorphism has been consistently associated with @entity6 , @entity4 , and @entity2 in Caucasians. Recently, large polymorphic segmental duplications resulting into complex rearrangements at this locus with a high diversity range in @entity0 populations have been revealed. We sought to explore whether the two multi-allelic copy number variants that are present in the H1 clade (with segmental duplications of 300 and 218   kilobases in length) could be responsible for the known H1-related risk of developing these @entity1 . A total of 857 Spanish subjects including 330 @entity0 with @entity2 , 96 with @entity6 , 55 with @entity4 , 51 @entity3 with @entity5 , and 325 neurologically healthy controls, were genotyped for the @entity7 haplotype. Subsequently, the two copy number variants that are characteristic of the H1 haplotype were evaluated through a high-resolution approach based on droplet digital polymerase chain reaction, in all H1 homozygous subjects. The H1 allele was significantly overrepresented in all diagnostic groups compared with controls ( @entity2 , P   =   0.0001; @entity6 , P   =   1.22   *   10(-6) ; @entity4 , P   =   0.0002; and @entity3 with @entity5 , P   =   0.032). However, no dosage differences were found for any of the two copy number variants analyzed. The H1 haplotype is associated with the risk of several @entity1 , including @entity3 with @entity5 . However, common structural diversity within the 17q21.31-H1 clade does not explain this genetic association.    2015 Wiley Periodicals, Inc.

title: Copy number variation analysis of the 17q21.31 region and its role in XXXX .

answer: @entity1


abstract: The @entity0 -containing @entity1 dismutase from @entity3 is inactivated by @entity2 to a limit of approximately 90%. When corrected for the @entity2 -resistant portion, this inactivation was first order with respect to residual activity and exhibited a pseudo-first-order rate constant of 0.066 min-1 at 25 degrees C in 0.24 mM @entity2 at pH 7.8. The @entity1 dismutase activity remaining after treatment with @entity2 differed from the activity of the native enzyme with respect to heat stability, inhibition by @entity7 , and inactivation by light in the presence of rose bengal and by @entity10 . The native and the @entity2 -modified enzymes were indistinguishable by electrophoresis on @entity8 gels. Inactivation of the enzyme by @entity2 was accompanied by loss of @entity6 and some loss of @entity0 , but there was no detectable loss of @entity9 or of other @entity5 . @entity2 treatment caused changes in the optical spectrum of the enzyme. Inactivation of the enzyme by @entity2 depends upon the @entity0 at the active site. Thus, the apoenzyme and the @entity4 -substituted enzyme were unaffected by @entity2 . We conclude that reaction of @entity2 with the @entity0 at the active site generates a potent oxidant capable of attacking @entity6 residues. A mechanism is proposed.

title: Effect of hydrogen peroxide on the @entity0 -containing XXXX dismutase of @entity3 .

answer: @entity1


abstract: The @entity0 -containing @entity1 dismutase from @entity3 is inactivated by @entity2 to a limit of approximately 90%. When corrected for the @entity2 -resistant portion, this inactivation was first order with respect to residual activity and exhibited a pseudo-first-order rate constant of 0.066 min-1 at 25 degrees C in 0.24 mM @entity2 at pH 7.8. The @entity1 dismutase activity remaining after treatment with @entity2 differed from the activity of the native enzyme with respect to heat stability, inhibition by @entity7 , and inactivation by light in the presence of rose bengal and by @entity10 . The native and the @entity2 -modified enzymes were indistinguishable by electrophoresis on @entity8 gels. Inactivation of the enzyme by @entity2 was accompanied by loss of @entity6 and some loss of @entity0 , but there was no detectable loss of @entity9 or of other @entity5 . @entity2 treatment caused changes in the optical spectrum of the enzyme. Inactivation of the enzyme by @entity2 depends upon the @entity0 at the active site. Thus, the apoenzyme and the @entity4 -substituted enzyme were unaffected by @entity2 . We conclude that reaction of @entity2 with the @entity0 at the active site generates a potent oxidant capable of attacking @entity6 residues. A mechanism is proposed.

title: Effect of hydrogen peroxide on the @entity0 -containing @entity1 dismutase of XXXX .

answer: @entity3


abstract: The @entity0 -containing @entity1 dismutase from @entity3 is inactivated by @entity2 to a limit of approximately 90%. When corrected for the @entity2 -resistant portion, this inactivation was first order with respect to residual activity and exhibited a pseudo-first-order rate constant of 0.066 min-1 at 25 degrees C in 0.24 mM @entity2 at pH 7.8. The @entity1 dismutase activity remaining after treatment with @entity2 differed from the activity of the native enzyme with respect to heat stability, inhibition by @entity7 , and inactivation by light in the presence of rose bengal and by @entity10 . The native and the @entity2 -modified enzymes were indistinguishable by electrophoresis on @entity8 gels. Inactivation of the enzyme by @entity2 was accompanied by loss of @entity6 and some loss of @entity0 , but there was no detectable loss of @entity9 or of other @entity5 . @entity2 treatment caused changes in the optical spectrum of the enzyme. Inactivation of the enzyme by @entity2 depends upon the @entity0 at the active site. Thus, the apoenzyme and the @entity4 -substituted enzyme were unaffected by @entity2 . We conclude that reaction of @entity2 with the @entity0 at the active site generates a potent oxidant capable of attacking @entity6 residues. A mechanism is proposed.

title: Effect of hydrogen peroxide on the XXXX -containing @entity1 dismutase of @entity3 .

answer: @entity0


abstract: High levels of @entity3 (TG) and free @entity4 ( @entity7 ) in maternal plasma, in @entity0 , promote fat passage to the fetus. In the @entity5 - @entity0 @entity1 a significant correlation exists between maternal plasma and fetal tissue lipid contents, as shown by the accretion of labeled @entity4 or @entity6 used as markers of maternal fat transfer. The passage of lipids through the placenta is not direct--this organ serves as an interim storage barrier with its lipid content increasing in proportion to the maternal TG and @entity7 level. Very low density lipoprotein (VLDL) TG are taken up with the aid of @entity8 as evident from TG = @entity2 exchange when doubly labeled VLDL-TG are presented to the placenta. Esterification rate of albumin-bound @entity7 is considerably higher indicating that the rate of TG lipolysis is rate limiting and that the @entity7 are the main precursor of the placental lipids. The uptake of both @entity7 and VLDL-TG is associated with the retention of a substantial amount of @entity7 in the placenta. The size of the @entity7 pool corresponds to the size of the extracellular fluid space. The @entity7 cannot be eluted by repeated washing, suggesting that they are membrane bound. Placental slices with prelabeled TG gradually release @entity7 into the medium upon reincubation with @entity7 -free albumin, indicating that TG and @entity7 traverse the placenta in part by a sequential process of esterification and lipolysis and in part by diffusion as @entity7 . The latter are probably moving from the maternal to the fetal side within the interfacial capillary membrane lipids.

title: Placental function in maternal-fetal fat transport in XXXX .

answer: @entity0


abstract: BACKGROUND: The purpose of our study was to describe and compare extensor mechanism injuries with regard to age, sex, body mass index (BMI), and comorbidities. METHODS: We identified @entity0 who had undergone surgical management of an extensor mechanism injury at two institutions between 1986 and 2012. Data analyzed included age at the time of surgery, sex, height, weight, and the presence of medical comorbidities. @entity0 with chronic @entity1 , those undergoing revision surgery, or those with injuries in the setting of total knee arthroplasty were excluded. RESULTS: Seven hundred and twenty-six @entity0 were included. There were 427 (58.8%) patellar @entity2 , 210 (28.9%) @entity1 @entity3 , and eighty-nine (12.3%) patellar @entity3 . Sixty-seven percent of the patellar @entity2 occurred in females, while 91% of the @entity1 and 95.5% of the patellar @entity3 occurred in males (p < 0.001). Age distribution was significantly different among the groups: the mean @entity0 age (and standard deviation) was 61.0    13.1 years (range, twenty to ninety-two years) for @entity3 , 56.3    17.4 years (range, sixteen to ninety-one years) for @entity2 , and 39.5    12.2 years (range, eighteen to seventy-two years) for @entity3 . @entity2 showed a bimodal distribution with regard to both age and sex: the median age of females was sixty-two years (range, sixteen to ninety-one years), and the median age of males was forty-seven years (range, sixteen to ninety-one years) (p < 0.001). BMI varied significantly among the cohorts: a mean of 25.0    5.2 kg/m(2) for @entity2 , 28.7    4.97 kg/m(2) for @entity3 , and 30.0    6.05 kg/m(2) for @entity3 (p < 0.001). Ninety-six percent of the females with a @entity5 had an underlying medical comorbidity compared with 68% of the males (p = 0.008). Of the @entity0 with underlying comorbidities, 61% of the females had comorbidities that were considered to be risk factors for @entity4 compared with 34% of the males (p = 0.008). CONCLUSIONS: Females with an extensor mechanism injury are more likely to sustain a @entity2 compared with males. Younger males are more likely to sustain a @entity2 or @entity3 ; however, we found that 43% of the patellar @entity3 were in @entity0 over the age of forty. Medical comorbidities were common with @entity3 , and we found that they were significantly more common in females than in males. CLINICAL RELEVANCE: Surgeons treating female @entity0 with a tendinous extensor mechanism disruption should have a low threshold to initiate a medical work-up in search of a possible undiagnosed medical comorbidity.

title: Extensor Mechanism Injuries of the Knee: Demographic Characteristics and Comorbidities from a Review of 726 XXXX Records.

answer: @entity0


abstract: The authors report eight cases of biliary duct @entity3 in @entity0 , examined by US and CT. There were five @entity0 and three @entity0 , aged 2 to 17 years. At presentation, US demonstrates the @entity1 mass within the liver or the hepatic hilum; it allows measurement of it and defines the relationship with portal vessels, biliary tract and other important structures. CT complements the US evaluation and determines operability. As US and CT cannot assess the histological origin of the @entity1 , a biopsy is mandatory before treatment. If complete surgical excision does not seem possible, percutaneous biopsy is preferable to incomplete excision and its possible complications. During the follow-up period, US can be repeated to measure @entity1 regression under chemotherapy. After surgery, CT seems preferable because of gas interposition. Both US and CT proved to be valuable for the early detection of local recurrence. The prognosis of these @entity1 remains bad. However, with more @entity2 and hopefully more efficient chemotherapy a precise evaluation of the @entity1 extension by US and CT is very important. Surgery will then be performed only on localized @entity1 or on residual masses after chemotherapy.

title: Ultrasonography and computed tomography for diagnosis and follow-up of biliary duct XXXX in @entity0 .

answer: @entity3


abstract: The authors report eight cases of biliary duct @entity3 in @entity0 , examined by US and CT. There were five @entity0 and three @entity0 , aged 2 to 17 years. At presentation, US demonstrates the @entity1 mass within the liver or the hepatic hilum; it allows measurement of it and defines the relationship with portal vessels, biliary tract and other important structures. CT complements the US evaluation and determines operability. As US and CT cannot assess the histological origin of the @entity1 , a biopsy is mandatory before treatment. If complete surgical excision does not seem possible, percutaneous biopsy is preferable to incomplete excision and its possible complications. During the follow-up period, US can be repeated to measure @entity1 regression under chemotherapy. After surgery, CT seems preferable because of gas interposition. Both US and CT proved to be valuable for the early detection of local recurrence. The prognosis of these @entity1 remains bad. However, with more @entity2 and hopefully more efficient chemotherapy a precise evaluation of the @entity1 extension by US and CT is very important. Surgery will then be performed only on localized @entity1 or on residual masses after chemotherapy.

title: Ultrasonography and computed tomography for diagnosis and follow-up of biliary duct @entity3 in XXXX .

answer: @entity0


abstract: The immune responses to SRBC and @entity3 were examined in immunized and non-immunized inbred @entity4 @entity0 at different times after an infection with Litomosoides carinii. During the infection, the T-cell dependent immune response to SRBC was significantly suppressed in non-immunized animals as compared to non infected controls. In contrast, after immunization with SRBC the antibody levels of infected animals were significantly higher in three of five events. At the onset of patency the response to SRBC was significantly depressed transiently in immunized animals. A corresponding @entity2 could be provoked by injections of isolated microfilariae as well as by FCS in immunized animals, @entity1 . The level of the antibodies was dependent on the density of microfilariae in the peripheral blood. The T-cell independent response to @entity3 was equal in non-immunized infected animals as in controls. After immunization with @entity3 during prepatency and at onset of patency a distinct but commensurate reaction was observed. Only after immunization at the peak of patency, the immune response of infected animals was significantly suppressed. In general, the antibody levels to @entity3 were not influenced by the microfilaremia.

title: T-cell dependent and T-cell independent immune response in normal and in with Litomosoides carinii infected XXXX @entity0 .

answer: @entity4


abstract: The immune responses to SRBC and @entity3 were examined in immunized and non-immunized inbred @entity4 @entity0 at different times after an infection with Litomosoides carinii. During the infection, the T-cell dependent immune response to SRBC was significantly suppressed in non-immunized animals as compared to non infected controls. In contrast, after immunization with SRBC the antibody levels of infected animals were significantly higher in three of five events. At the onset of patency the response to SRBC was significantly depressed transiently in immunized animals. A corresponding @entity2 could be provoked by injections of isolated microfilariae as well as by FCS in immunized animals, @entity1 . The level of the antibodies was dependent on the density of microfilariae in the peripheral blood. The T-cell independent response to @entity3 was equal in non-immunized infected animals as in controls. After immunization with @entity3 during prepatency and at onset of patency a distinct but commensurate reaction was observed. Only after immunization at the peak of patency, the immune response of infected animals was significantly suppressed. In general, the antibody levels to @entity3 were not influenced by the microfilaremia.

title: T-cell dependent and T-cell independent immune response in normal and in with Litomosoides carinii infected @entity4 XXXX .

answer: @entity0


abstract: BACKGROUND: This study aims to investigate @entity1 -binding myeloid-related protein (MRP)-8/14 in the saliva and serum of individuals with @entity2 and periodontally healthy individuals for the assessment of its role in the pathogenesis and clinical diagnosis of @entity2 . METHODS: This cross-sectional study includes 56 @entity0 with @entity2 and 44 periodontally healthy individuals. Saliva and serum were collected for the detection of @entity4 /14 and @entity1 levels. Periodontopathic bacteria were determined by polymerase chain reaction in saliva. Correlations between salivary and serum @entity4 /14 levels and clinical parameters, bacteria, and @entity1 were analyzed with Pearson correlation in a multiple regression model. @entity4 /14 levels were documented with receiver operating characteristic (ROC) curves. RESULTS: Compared with healthy individuals, @entity4 /14 levels were significantly higher in both the saliva and serum of @entity0 with @entity2 , but @entity1 was increased only in saliva. A high diagnostic potential of salivary @entity4 /14 was detected for @entity2 (ROC = 0.86). Salivary @entity4 /14 levels correlated significantly with the presence of the periodontopathogen @entity3 , as well as with the clinical parameters of @entity2 . CONCLUSION: @entity4 /14 in saliva might be a potential diagnostic parameter for periodontal disease.

title: Comparative Analysis of @entity1 -Binding Myeloid-Related Protein-8/14 in Saliva and Serum of @entity0 With XXXX and Healthy Individuals.

answer: @entity2


abstract: BACKGROUND: This study aims to investigate @entity1 -binding myeloid-related protein (MRP)-8/14 in the saliva and serum of individuals with @entity2 and periodontally healthy individuals for the assessment of its role in the pathogenesis and clinical diagnosis of @entity2 . METHODS: This cross-sectional study includes 56 @entity0 with @entity2 and 44 periodontally healthy individuals. Saliva and serum were collected for the detection of @entity4 /14 and @entity1 levels. Periodontopathic bacteria were determined by polymerase chain reaction in saliva. Correlations between salivary and serum @entity4 /14 levels and clinical parameters, bacteria, and @entity1 were analyzed with Pearson correlation in a multiple regression model. @entity4 /14 levels were documented with receiver operating characteristic (ROC) curves. RESULTS: Compared with healthy individuals, @entity4 /14 levels were significantly higher in both the saliva and serum of @entity0 with @entity2 , but @entity1 was increased only in saliva. A high diagnostic potential of salivary @entity4 /14 was detected for @entity2 (ROC = 0.86). Salivary @entity4 /14 levels correlated significantly with the presence of the periodontopathogen @entity3 , as well as with the clinical parameters of @entity2 . CONCLUSION: @entity4 /14 in saliva might be a potential diagnostic parameter for periodontal disease.

title: Comparative Analysis of XXXX -Binding Myeloid-Related Protein-8/14 in Saliva and Serum of @entity0 With @entity2 and Healthy Individuals.

answer: @entity1


abstract: BACKGROUND: This study aims to investigate @entity1 -binding myeloid-related protein (MRP)-8/14 in the saliva and serum of individuals with @entity2 and periodontally healthy individuals for the assessment of its role in the pathogenesis and clinical diagnosis of @entity2 . METHODS: This cross-sectional study includes 56 @entity0 with @entity2 and 44 periodontally healthy individuals. Saliva and serum were collected for the detection of @entity4 /14 and @entity1 levels. Periodontopathic bacteria were determined by polymerase chain reaction in saliva. Correlations between salivary and serum @entity4 /14 levels and clinical parameters, bacteria, and @entity1 were analyzed with Pearson correlation in a multiple regression model. @entity4 /14 levels were documented with receiver operating characteristic (ROC) curves. RESULTS: Compared with healthy individuals, @entity4 /14 levels were significantly higher in both the saliva and serum of @entity0 with @entity2 , but @entity1 was increased only in saliva. A high diagnostic potential of salivary @entity4 /14 was detected for @entity2 (ROC = 0.86). Salivary @entity4 /14 levels correlated significantly with the presence of the periodontopathogen @entity3 , as well as with the clinical parameters of @entity2 . CONCLUSION: @entity4 /14 in saliva might be a potential diagnostic parameter for periodontal disease.

title: Comparative Analysis of @entity1 -Binding Myeloid-Related Protein-8/14 in Saliva and Serum of XXXX With @entity2 and Healthy Individuals.

answer: @entity0


abstract: BACKGROUND: Herbal agents such as Aloe vera (AV) have been used in medical and dental therapy for thousands of years. AV has anti-inflammatory, antioxidant, antimicrobial, hypoglycemic, healing-promoting, and immune-boosting properties. This study aims to investigate the clinical effectiveness of locally delivered AV gel used as an adjunct to scaling and root planing (SRP) in the treatment of @entity0 with @entity1 ( @entity1 ) and @entity3 ( @entity3 ). METHODS: Sixty @entity0 with @entity2 ( @entity2 ) >= 5 mm and clinical attachment level (CAL) >= 3 mm were randomly divided into two groups. All @entity0 underwent SRP. Placebo gel was locally delivered to group 1 and AV gel to group 2. Full-mouth plaque index (PI), modified sulcus bleeding index (mSBI), @entity2 , and CAL were recorded at baseline and 3 and 6 months. RESULTS: @entity0 in group 2 showed significantly greater mean reductions in PI, mSBI, and @entity2 and mean gain in CAL compared with those in group 1 from baseline to 3 months. Gain in CAL was significantly greater in group 2 at all time intervals versus group 1. CONCLUSION: Adjunctive use of locally delivered AV gel, in comparison to locally delivered placebo gel, is associated with greater reduction in PI, mSBI, and @entity2 as well as more gain in CAL in @entity0 with @entity1 and @entity3 .

title: Adjunctive Local Delivery of Aloe Vera Gel in @entity0 With Type 2 Diabetes and XXXX : A Randomized, Controlled Clinical Trial.

answer: @entity3


abstract: BACKGROUND: Herbal agents such as Aloe vera (AV) have been used in medical and dental therapy for thousands of years. AV has anti-inflammatory, antioxidant, antimicrobial, hypoglycemic, healing-promoting, and immune-boosting properties. This study aims to investigate the clinical effectiveness of locally delivered AV gel used as an adjunct to scaling and root planing (SRP) in the treatment of @entity0 with @entity1 ( @entity1 ) and @entity3 ( @entity3 ). METHODS: Sixty @entity0 with @entity2 ( @entity2 ) >= 5 mm and clinical attachment level (CAL) >= 3 mm were randomly divided into two groups. All @entity0 underwent SRP. Placebo gel was locally delivered to group 1 and AV gel to group 2. Full-mouth plaque index (PI), modified sulcus bleeding index (mSBI), @entity2 , and CAL were recorded at baseline and 3 and 6 months. RESULTS: @entity0 in group 2 showed significantly greater mean reductions in PI, mSBI, and @entity2 and mean gain in CAL compared with those in group 1 from baseline to 3 months. Gain in CAL was significantly greater in group 2 at all time intervals versus group 1. CONCLUSION: Adjunctive use of locally delivered AV gel, in comparison to locally delivered placebo gel, is associated with greater reduction in PI, mSBI, and @entity2 as well as more gain in CAL in @entity0 with @entity1 and @entity3 .

title: Adjunctive Local Delivery of Aloe Vera Gel in XXXX With Type 2 Diabetes and @entity3 : A Randomized, Controlled Clinical Trial.

answer: @entity0


abstract: @entity4 ( @entity4 ) is a @entity3 arising from mutations in b-d-glucuronidase ( @entity5 ), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including @entity0 . Herein, @entity4 @entity2 were injected intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna magna with AAV9 or AAVrh10 vectors carrying the @entity2 @entity5 cDNA. Although i.v. injection alone at 3 days of age resulted in normal cerebrospinal fluid (CSF) @entity5 activity, brain tissue homogenates had only ~1 to 6% normal @entity5 activity and continued to have elevated GAG storage. In contrast, i.t. injection at 3 weeks of age resulted in CSF @entity5 activity 44-fold normal while brain tissue homogenates had >100% normal @entity5 activity and reduced GAGs compared with untreated @entity2 . Markers for secondary storage and @entity1 were eliminated in i.t.-treated @entity2 and reduced in i.v.-treated @entity2 compared with untreated @entity2 . Given that i.t.-treated @entity2 expressed higher levels of @entity5 in the CNS tissues compared to those treated i.v., we conclude that i.t. injection of AAV9 or AAVrh10 vectors is more effective than i.v. injection alone in the large animal model of @entity4 .

title: Evaluation of AAV-mediated Gene Therapy for Central XXXX in @entity2 @entity4 .

answer: @entity0


abstract: @entity4 ( @entity4 ) is a @entity3 arising from mutations in b-d-glucuronidase ( @entity5 ), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including @entity0 . Herein, @entity4 @entity2 were injected intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna magna with AAV9 or AAVrh10 vectors carrying the @entity2 @entity5 cDNA. Although i.v. injection alone at 3 days of age resulted in normal cerebrospinal fluid (CSF) @entity5 activity, brain tissue homogenates had only ~1 to 6% normal @entity5 activity and continued to have elevated GAG storage. In contrast, i.t. injection at 3 weeks of age resulted in CSF @entity5 activity 44-fold normal while brain tissue homogenates had >100% normal @entity5 activity and reduced GAGs compared with untreated @entity2 . Markers for secondary storage and @entity1 were eliminated in i.t.-treated @entity2 and reduced in i.v.-treated @entity2 compared with untreated @entity2 . Given that i.t.-treated @entity2 expressed higher levels of @entity5 in the CNS tissues compared to those treated i.v., we conclude that i.t. injection of AAV9 or AAVrh10 vectors is more effective than i.v. injection alone in the large animal model of @entity4 .

title: Evaluation of AAV-mediated Gene Therapy for Central @entity0 in @entity2 XXXX .

answer: @entity4


abstract: @entity4 ( @entity4 ) is a @entity3 arising from mutations in b-d-glucuronidase ( @entity5 ), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including @entity0 . Herein, @entity4 @entity2 were injected intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna magna with AAV9 or AAVrh10 vectors carrying the @entity2 @entity5 cDNA. Although i.v. injection alone at 3 days of age resulted in normal cerebrospinal fluid (CSF) @entity5 activity, brain tissue homogenates had only ~1 to 6% normal @entity5 activity and continued to have elevated GAG storage. In contrast, i.t. injection at 3 weeks of age resulted in CSF @entity5 activity 44-fold normal while brain tissue homogenates had >100% normal @entity5 activity and reduced GAGs compared with untreated @entity2 . Markers for secondary storage and @entity1 were eliminated in i.t.-treated @entity2 and reduced in i.v.-treated @entity2 compared with untreated @entity2 . Given that i.t.-treated @entity2 expressed higher levels of @entity5 in the CNS tissues compared to those treated i.v., we conclude that i.t. injection of AAV9 or AAVrh10 vectors is more effective than i.v. injection alone in the large animal model of @entity4 .

title: Evaluation of AAV-mediated Gene Therapy for Central @entity0 in XXXX @entity4 .

answer: @entity2


abstract: UNASSIGNED: Although supraclavicular @entity7 (SCBPB) was repopularized by the introduction of ultrasound, its usefulness in shoulder surgery has not been widely reported. The objective of this study was to compare motor and sensory blockades, the incidence of side effects, and intraoperative opioid analgesic requirements between SCBPB and interscalene @entity7 (ISBPB) in @entity0 undergoing arthroscopic shoulder surgery. @entity0 were randomly assigned to 1 of 2 groups (ISBPB group: n=47; SCBPB group: n=46). The side effects of the @entity7 ( @entity6 , hoarseness, and subjective @entity4 ), the sensory block score (graded from 0 [no cold sensation] to 100 [intact sensation] using an @entity2 swab) for each of the 5 dermatomes (C5-C8 and T1), and the motor block score (graded from 0 [complete paralysis] to 6 [normal muscle force]) for muscle forces corresponding to the radial, ulnar, median, and musculocutaneous nerves were evaluated 20 min after the @entity7 . @entity5 was administered in 50  g increments when the @entity0 complained of @entity1 that was not relieved by the @entity7 .There were no conversions to general anesthesia due to a failed @entity7 . The sensory block scores for the C5 to C8 dermatomes were significantly lower in the ISBPB group. However, the percentage of @entity0 who received @entity5 was comparable between the 2 groups (27.7% [ISBPB group] and 30.4% [SCBPB group], P=0.77). SCBPB produced significantly lower motor block scores for the radial, ulnar, and median nerves than did ISBPB. A significantly higher incidence of @entity6 was observed in the ISBPB group (59.6% [ISBPB group] and 19.6% [SCBPB group], P<0.001). No @entity0 complained of subjective @entity4 .Despite the weaker degree of sensory blockade provided by SCBPB in comparison to ISBPB, opioid analgesic requirements are similar during arthroscopic shoulder surgery under both brachial @entity3 . However, SCBPB produces a better motor blockade and a lower incidence of @entity6 than ISBPB.

title: Comparison Between Ultrasound-Guided Supraclavicular and Interscalene Brachial Plexus Blocks in XXXX Undergoing Arthroscopic Shoulder Surgery: A Prospective, Randomized, Parallel Study.

answer: @entity0


abstract: Information from animal studies has demonstrated the harmful effects of @entity3 supplementation on @entity5 transport. Although some studies have been carried out in @entity0 , the effect on @entity0 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity0 and 21 @entity0 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity3 (as 220 mg @entity7 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity5 and @entity3 . Symptoms, which included @entity1 , abdominal cramps, @entity4 , @entity6 , were registered from 84% of @entity0 and 18% of @entity0 . Six female volunteers discontinued the trial; five owing to @entity2 and one owing to consistent @entity1 . Plasma @entity3 levels rose significantly in both @entity0 and @entity0 , the increase being 36% and 57%, respectively. Plasma @entity5 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity3 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity3 a day on plasma @entity5 levels in healthy volunteers over a period of six weeks.

title: The effect of XXXX supplements on plasma @entity3 and @entity5 levels and the reported symptoms in healthy volunteers.

answer: @entity3


abstract: Information from animal studies has demonstrated the harmful effects of @entity3 supplementation on @entity5 transport. Although some studies have been carried out in @entity0 , the effect on @entity0 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity0 and 21 @entity0 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity3 (as 220 mg @entity7 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity5 and @entity3 . Symptoms, which included @entity1 , abdominal cramps, @entity4 , @entity6 , were registered from 84% of @entity0 and 18% of @entity0 . Six female volunteers discontinued the trial; five owing to @entity2 and one owing to consistent @entity1 . Plasma @entity3 levels rose significantly in both @entity0 and @entity0 , the increase being 36% and 57%, respectively. Plasma @entity5 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity3 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity3 a day on plasma @entity5 levels in healthy volunteers over a period of six weeks.

title: The effect of @entity3 supplements on plasma XXXX and @entity5 levels and the reported symptoms in healthy volunteers.

answer: @entity3


abstract: Information from animal studies has demonstrated the harmful effects of @entity3 supplementation on @entity5 transport. Although some studies have been carried out in @entity0 , the effect on @entity0 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity0 and 21 @entity0 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity3 (as 220 mg @entity7 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity5 and @entity3 . Symptoms, which included @entity1 , abdominal cramps, @entity4 , @entity6 , were registered from 84% of @entity0 and 18% of @entity0 . Six female volunteers discontinued the trial; five owing to @entity2 and one owing to consistent @entity1 . Plasma @entity3 levels rose significantly in both @entity0 and @entity0 , the increase being 36% and 57%, respectively. Plasma @entity5 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity3 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity3 a day on plasma @entity5 levels in healthy volunteers over a period of six weeks.

title: The effect of @entity3 supplements on plasma @entity3 and XXXX levels and the reported symptoms in healthy volunteers.

answer: @entity5


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity4 ( @entity7 ) limits its effectiveness against @entity1 cells. @entity8 ( @entity9 ) has been reported to reduce MDR in various types of @entity1 , but the mechanisms involving Ras and @entity5 ( @entity5 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9 in reversing MDR to @entity7 , and to identify the association in antitumor activities between the effectiveness of @entity7 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity0 @entity3 cell lines. @entity2 and sensitivity towards @entity9 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity0 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9 . The SGC7901/ADM cells were resistant to @entity7 and @entity9 treatment reduced the level of resistance to @entity7 (P<0.01). The expression of @entity5 ( @entity5 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity6 remained the same. @entity9 decreased the levels of Ras and p  - @entity6 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity6 were further decreased (P<0.01). Drug  -resistant @entity3 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity6 . Non  - and mildly  -toxic doses of @entity9 reduced MDR to @entity7 through Ras/p- @entity6 signaling.

title: Downregulation of @entity5 , Ras and p- @entity6 contributes to the @entity8 -induced reduction in drug resistance towards XXXX in @entity3 cell lines.

answer: @entity4


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity4 ( @entity7 ) limits its effectiveness against @entity1 cells. @entity8 ( @entity9 ) has been reported to reduce MDR in various types of @entity1 , but the mechanisms involving Ras and @entity5 ( @entity5 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9 in reversing MDR to @entity7 , and to identify the association in antitumor activities between the effectiveness of @entity7 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity0 @entity3 cell lines. @entity2 and sensitivity towards @entity9 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity0 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9 . The SGC7901/ADM cells were resistant to @entity7 and @entity9 treatment reduced the level of resistance to @entity7 (P<0.01). The expression of @entity5 ( @entity5 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity6 remained the same. @entity9 decreased the levels of Ras and p  - @entity6 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity6 were further decreased (P<0.01). Drug  -resistant @entity3 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity6 . Non  - and mildly  -toxic doses of @entity9 reduced MDR to @entity7 through Ras/p- @entity6 signaling.

title: Downregulation of @entity5 , Ras and p- @entity6 contributes to the @entity8 -induced reduction in drug resistance towards @entity4 in XXXX cell lines.

answer: @entity3


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity4 ( @entity7 ) limits its effectiveness against @entity1 cells. @entity8 ( @entity9 ) has been reported to reduce MDR in various types of @entity1 , but the mechanisms involving Ras and @entity5 ( @entity5 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9 in reversing MDR to @entity7 , and to identify the association in antitumor activities between the effectiveness of @entity7 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity0 @entity3 cell lines. @entity2 and sensitivity towards @entity9 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity0 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9 . The SGC7901/ADM cells were resistant to @entity7 and @entity9 treatment reduced the level of resistance to @entity7 (P<0.01). The expression of @entity5 ( @entity5 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity6 remained the same. @entity9 decreased the levels of Ras and p  - @entity6 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity6 were further decreased (P<0.01). Drug  -resistant @entity3 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity6 . Non  - and mildly  -toxic doses of @entity9 reduced MDR to @entity7 through Ras/p- @entity6 signaling.

title: Downregulation of @entity5 , Ras and p- XXXX contributes to the @entity8 -induced reduction in drug resistance towards @entity4 in @entity3 cell lines.

answer: @entity6


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity4 ( @entity7 ) limits its effectiveness against @entity1 cells. @entity8 ( @entity9 ) has been reported to reduce MDR in various types of @entity1 , but the mechanisms involving Ras and @entity5 ( @entity5 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9 in reversing MDR to @entity7 , and to identify the association in antitumor activities between the effectiveness of @entity7 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity0 @entity3 cell lines. @entity2 and sensitivity towards @entity9 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity0 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9 . The SGC7901/ADM cells were resistant to @entity7 and @entity9 treatment reduced the level of resistance to @entity7 (P<0.01). The expression of @entity5 ( @entity5 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity6 remained the same. @entity9 decreased the levels of Ras and p  - @entity6 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity6 were further decreased (P<0.01). Drug  -resistant @entity3 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity6 . Non  - and mildly  -toxic doses of @entity9 reduced MDR to @entity7 through Ras/p- @entity6 signaling.

title: Downregulation of XXXX , Ras and p- @entity6 contributes to the @entity8 -induced reduction in drug resistance towards @entity4 in @entity3 cell lines.

answer: @entity5


abstract: UNASSIGNED: Multidrug resistance (MDR) to @entity4 ( @entity7 ) limits its effectiveness against @entity1 cells. @entity8 ( @entity9 ) has been reported to reduce MDR in various types of @entity1 , but the mechanisms involving Ras and @entity5 ( @entity5 ) remain to be fully elucidated. The objectives of the present study were to evaluate @entity9 in reversing MDR to @entity7 , and to identify the association in antitumor activities between the effectiveness of @entity7 and Ras/phosphorylated (p  -) extracellular signal  -regulated kinase (ERK)1/2  signaling in SGC7901/ADM and SGC7901/S @entity0 @entity3 cell lines. @entity2 and sensitivity towards @entity9 were assessed using non  -toxic and mildly  -toxic concentrations (0.1  and  0.5    M, respectively). The reversing effect of @entity9 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant @entity0 granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to @entity9 . The SGC7901/ADM cells were resistant to @entity7 and @entity9 treatment reduced the level of resistance to @entity7 (P<0.01). The expression of @entity5 ( @entity5 ) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). @entity9 treatment decreased the levels of P  -gp in a time  - and dose  -dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p  - @entity6 remained the same. @entity9 decreased the levels of Ras and p  - @entity6 (P<0.01). Following pretreatment with rhG  -CSF, the levels of Ras and p  - @entity6 were further decreased (P<0.01). Drug  -resistant @entity3 cells had higher expression levels of P  -gp and Ras, but not of p  - @entity6 . Non  - and mildly  -toxic doses of @entity9 reduced MDR to @entity7 through Ras/p- @entity6 signaling.

title: Downregulation of @entity5 , Ras and p- @entity6 contributes to the XXXX -induced reduction in drug resistance towards @entity4 in @entity3 cell lines.

answer: @entity8


abstract: UNASSIGNED: Over the last decades @entity1 has become a major health problem worldwide. The only specific treatment to date is @entity9 ( @entity9 ). Although it was shown that @entity9 generates allergen-tolerant T cells, detailed mechanism underlying its activity is still unclear and there is no reliable method to monitor its effectiveness. The aim of our study was to evaluate @entity9 influence on the frequency of @entity2 ( @entity2 ) Tregs in allergic @entity0 with various clinical manifestations. The relative number of @entity2 Tregs in 32 blood samples from allergic @entity0 at baseline and/or after 1 year of @entity9 was assessed by flow cytometry. In the entire studied group, the percentage of @entity2 Tregs did not increase 1 year after @entity9 . Nevertheless, the percentage of @entity2 Tregs after @entity9 significantly increased in @entity0 with @entity5 ( @entity6 , @entity4 , and @entity7 ) coexisting with nonrespiratory manifestations ( @entity8 and/or @entity3 ), whereas, in @entity0 with @entity5 only, the percentage of @entity2 Tregs decreased. To the best of our knowledge, this is the first report showing various differential @entity2 Tregs response to @entity9 in allergic @entity0 . @entity2 Tregs number could be useful in treatment monitoring. Further studies are warranted to confirm these observations.

title: XXXX Tregs Response to Sublingual Allergen Specific Immunotherapy in @entity0 Depends on the Manifestation of Allergy.

answer: @entity2


abstract: UNASSIGNED: Over the last decades @entity1 has become a major health problem worldwide. The only specific treatment to date is @entity9 ( @entity9 ). Although it was shown that @entity9 generates allergen-tolerant T cells, detailed mechanism underlying its activity is still unclear and there is no reliable method to monitor its effectiveness. The aim of our study was to evaluate @entity9 influence on the frequency of @entity2 ( @entity2 ) Tregs in allergic @entity0 with various clinical manifestations. The relative number of @entity2 Tregs in 32 blood samples from allergic @entity0 at baseline and/or after 1 year of @entity9 was assessed by flow cytometry. In the entire studied group, the percentage of @entity2 Tregs did not increase 1 year after @entity9 . Nevertheless, the percentage of @entity2 Tregs after @entity9 significantly increased in @entity0 with @entity5 ( @entity6 , @entity4 , and @entity7 ) coexisting with nonrespiratory manifestations ( @entity8 and/or @entity3 ), whereas, in @entity0 with @entity5 only, the percentage of @entity2 Tregs decreased. To the best of our knowledge, this is the first report showing various differential @entity2 Tregs response to @entity9 in allergic @entity0 . @entity2 Tregs number could be useful in treatment monitoring. Further studies are warranted to confirm these observations.

title: @entity2 Tregs Response to Sublingual Allergen Specific Immunotherapy in XXXX Depends on the Manifestation of Allergy.

answer: @entity0


abstract: UNASSIGNED: @entity3 mesylate is approved for the adjuvant treatment of KIT-positive @entity2 ( @entity2 ) following surgical resection. However, uncertainty remains in terms of @entity0 eligibility for adjuvant treatment and the optimal duration of treatment. Here, we present two challenging @entity0 cases encountered in clinical practice that highlight the ambiguity in the current recommendations for adjuvant @entity3 in @entity2 and discuss our approaches and rationales for treatment. The first case involves a 36-year-old @entity0 with a 7   cm duodenal @entity2 and possible @entity1 rupture during surgical resection. This @entity0 's risk of @entity2 recurrence was either intermediate or high depending on which risk stratification criteria were used. The @entity0 was treated with adjuvant @entity3 for 3 years and experienced disease recurrence 14 months after the completion of treatment. @entity3 treatment was reintroduced, and the @entity0 is in partial response 17 months later. The second case involves a 46-year-old @entity0 at high risk of recurrence following surgical resection. Adjuvant treatment with @entity3 was initiated. After considering the @entity0 's initial high risk and good side-effect profile, the decision was made to continue adjuvant @entity3 treatment for 5 years. As of May 2013, the @entity0 has been receiving continuous @entity3 treatment for 52 months, with no sign of progression. These reports exemplify the challenges faced in clinical practice because of uncertainties in optimal risk stratification criteria and duration of treatment. They stress the importance of individualized treatment and shared decision making between the physician and the @entity0 .

title: Adjuvant @entity3 treatment in XXXX : which risk stratification criteria and for how long? A case report.

answer: @entity2


abstract: UNASSIGNED: @entity3 mesylate is approved for the adjuvant treatment of KIT-positive @entity2 ( @entity2 ) following surgical resection. However, uncertainty remains in terms of @entity0 eligibility for adjuvant treatment and the optimal duration of treatment. Here, we present two challenging @entity0 cases encountered in clinical practice that highlight the ambiguity in the current recommendations for adjuvant @entity3 in @entity2 and discuss our approaches and rationales for treatment. The first case involves a 36-year-old @entity0 with a 7   cm duodenal @entity2 and possible @entity1 rupture during surgical resection. This @entity0 's risk of @entity2 recurrence was either intermediate or high depending on which risk stratification criteria were used. The @entity0 was treated with adjuvant @entity3 for 3 years and experienced disease recurrence 14 months after the completion of treatment. @entity3 treatment was reintroduced, and the @entity0 is in partial response 17 months later. The second case involves a 46-year-old @entity0 at high risk of recurrence following surgical resection. Adjuvant treatment with @entity3 was initiated. After considering the @entity0 's initial high risk and good side-effect profile, the decision was made to continue adjuvant @entity3 treatment for 5 years. As of May 2013, the @entity0 has been receiving continuous @entity3 treatment for 52 months, with no sign of progression. These reports exemplify the challenges faced in clinical practice because of uncertainties in optimal risk stratification criteria and duration of treatment. They stress the importance of individualized treatment and shared decision making between the physician and the @entity0 .

title: Adjuvant XXXX treatment in @entity2 : which risk stratification criteria and for how long? A case report.

answer: @entity3